DB05698InvestigationalVaccines
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
- Mechanism
- Curator reviewed
Upon administration, GI-4000 vaccine elicits an immune response by stimulating a specific cytotoxic T-cell response against the mutated forms of Ras. This may lead to a destruction of cancer cells expressing a Ras mutation.
- Primary indication
- Investigated for use/treatment in pancreatic cancer.Curator reviewed
- Code names
- GI-4000
What you can answer from here — as of June 12, 2020
Which companies are running trials of GI-4000, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account